Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

Inclusion Criteria: * Children with a new diagnosis of Crohn's Disease and whose physician has not yet initiated corticosteroid treatment (10 Subjects): * Clinical diagnosis within the previous 21 days * Above age 7 and younger than age 18 * Signed informed consent statement and assent statement. * Children with a new diagnosis of Ulcerative Colitis and whose physician has not yet initiated corticosteroid treatment (10 Subjects): * Clinical diagnosis within the previous 21 days * Above age 7 and younger than age 18 * Signed informed consent statement and assent statement. * Children with Crohn's Disease whose physician has initiated Infliximab treatment for the first time (10 Subjects): * Clinical diagnosis of Crohn's Disease * Above age 7 and younger that age 18 * Signed informed consent statement and assent statement. * Children with Ulcerative Colitis whose physician has initiated Infliximab treatment for the first time (10 Subjects): * Clinical diagnosis of Ulcerative Colitis * Above age 7 and younger than age 18 * Signed informed consent statement and assent statement. * Healthy Controls (10 Subjects): * Above age 7 and younger than age 18 * otherwise healthy, with no intercurrent illness as determined by a member of the study team using the eligibility checklist * controls will be gender and age (± 2 years) matched to the patient groups described above * Signed informed consent statement and assent statement Exclusion Criteria: * unwilling to give consent for this study. * child with prior prescription and administration of Infliximab